This fact sheet reviews the PSA test for prostate cancer, in particular screening recommendations, test limitations, and possible improvements the future may hold in store for the test.
Among persons 65 years or older with limited life expectancies of less than 10 years, an estimated 15.7% may have undergone nonrecommended screenings for prostate and breast cancers.
Enzalutamide significantly reduced the risk of prostate cancer progression or death in prostate cancer.
Phase 3 results of the TRAPEZE trial of patients with bony metastatic castrate-refractory prostate cancer (CRPC).
The risk of lethal prostate cancer, but not of overall, high-grade, or advanced cancers, was reduced with regular aspirin use.
Novel Diagnostic Test Uses CTCs in Blood to Guide Treatment Decisions for Patients With Prostate Cancer
An experimental liquid biopsy using a blood sample may determine which patients with prostate cancer will benefit from hormone therapies.
Important discussions about prostate cancer screening and treatment are not occurring between men and their health care team.
A total of 40% of patients with mCRPC treated with docetaxel after abiraterone achieved at least a 50% reduction in PSA, according to a study presented at the 2016 Genitourinary Cancers Symposium.
African American men with Gleason score 3+3=6 prostate cancer produce less PSA and have significantly lower PSA density than white men, according to a new study. These findings could have important implications for treatment decision-making.
Risks of Adverse Effects Lower With Surgical Castration Vs. Chemical Castration for Metastatic Prostate Cancer
Surgical castration via orchiectomy for metastatic prostate cancer is associated with lower risks for adverse effects compared with medical castration via GnRHa therapy.
Twins carry a significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a long-term follow-up study of twins in Nordic countries.
Gonadotropin-releasing hormone agonist (GnRHa) therapy is associated with increased risks of numerous clinically relevant adverse events compared with orchiectomy.
A study compared the number of adverse events caused by both intermittent and continuous androgen-deprivation therapy (ADT) for prostate cancer.
Patients with prostate cancer who have undergone radical prostatectomy have largely unrealistic expectations with respect to their postoperative sexual function.
Docetaxel should be added at initiation of standard of care treatment in men with prostate cancer; however, no evidence of survival improvement was seen with zoledronic acid therefore it is not recommended as part of standard of care for this patient population.
Tumor Location and Duration of Therapy Influence Palliative Effects of Radiation Therapy for Painful Bone Metastases
In a review of the Dutch Bone Metastasis Study results, stratified for primary tumor location, palliative radiation therapy was found to reduce pain and improve quality of life for some patients.
Repeating PSA Test in Select Patients Can Mitigate Controversial Issues in Prostate Cancer Screening
Some task forces advocate abandoning the use of the screening PSA test because it leads to unnecessary prostate biopsies. Canadian researchers show that repeating the test in select patients can reduce the number of biopsies.
Economic burden is significantly higher for survivors of colorectal, breast, and prostate cancers compared with persons with no cancer history; however, excess economic burden attributable to cancer varies by cancer site and age.
In a study that demonstrates the emerging technique of extracting biomedical data from ordinary patient medical records, a nearly 2-fold increase was seen in the rate of Alzheimer disease diagnoses among men with prostate cancer who received ADT.
Men with prostate cancer are at risk for brittle bones as an adverse effect of their treatment; however, 1 hour of soccer training a few times a week counters many of the negative effects of treatment.
A method to better trace changes in cancers and treatment of the prostate and lung without the limitations associated with radiation has been developed.
A study that tracked tens of thousands of midlife and older men for more than 20 years has found that vigorous exercise and other healthy lifestyle habits may reduce their chances of developing a lethal type of prostate cancer by up to 68%.
Men undergoing active surveillance for low-risk prostate cancer may not be receiving proper monitoring.
The impact on PSA screening and prostate cancer incidence before and after the 2012 USPSTF screening recommendations were examined in two recent studies.
A small study shows those undergoing radiation therapy had fewer side effects and less fatigue when practicing yoga.
A new test is better at detecting aggressive prostate cancer than measuring PSA levels. The new test discovers aggressive cancer earlier and reduces the number of false positive tests and unnecessary biopsies.
Blood Test Identifies Mutations Behind Drug Resistance in Patients Taking Antiandrogen for Prostate Cancer
Scientists developed a blood test that can identify key mutations driving resistance to a widely used prostate cancer drug and which patients will not respond to the treatment in advance.
Patients who are undergoing radiotherapy for prostate cancer may benefit from yoga.
Both the incidence of early stage prostate cancer and rates of prostate-specific antigen (PSA) screening oincide with the 2012 USPSTF recommendation.
Androgen deprivation therapy is associated with declines in self-reported physical functioning and upper body muscle strength.
The cost of treatment for low-risk prostate cancer varies widely. A new study examined the cost of care from when a patient checks in for his first appointment through his posttreatment follow-up testing via the use of time-driven activity-based costing.
For veterans with early-stage prostate cancer, patient age and tumor risk were found to be more strongly associated with use of expectant management.
Older black men with localized prostate cancer were more likely to have poorer quality care, incur higher costs, and have worse postoperative outcomes than white men. However, that did not translate to worse overall or cancer-specific survival.
Overall survival in men with rising PSA levels after prostatectomy for prostate cancer was statistically improved by adding a 24-month course of AAT during and after salvage radiotherapy, compared with salvage radiotherapy alone.
Clinical trial results confirm that newly diagnosed early stage prostate cancer can be treated with hypofractionated radiotherapy and experience the same level of cancer control as those treated with conventional radiotherapy.
A high response rate was seen among patients whose metastatic castration-resistant prostate cancers had DNA-repair defects.
Scientists have gained a key insight into how prostate tumors get their start. Instead of rewriting the normal DNA code, the master regulator of genes in prostate cells is reprogrammed to drive malignant growth.
Black patients treated with radical prostatectomy for localized prostate cancer (PCa) are more likely to experience adverse events.
No reduction in risk of distant metastasis, cancer-related deaths, radiation-linked adverse effects were connected to the use of men's health supplements (MHSs).
Use of testosterone therapy has increased in the last decade and the potential long-term risks associated with this therapy have been of concern.
Researchers identified two new cancer-causing gene mutations that could lead to more targeted and effective treatments for certain lung and prostate cancers.
In the study, management was changed in 44% more cases by Use of the imaging agent Ga-68 PSMA with PET/CT resulted in a change in management of prostate cancer in 44% more cases than with another widely used agent.
Evidence suggests that androgen deprivation therapy is associated with nonfatal cardiovascular events.
A recent study examined the potential benefits and potential downsides to the USPSTF recommendation against regular PSA screening.
Electronic triggers designed to search for key data were able to identify and reduce follow-up delays for patients being evaluated for a diagnosis of colon or prostate cancer.
A molecular imaging biomarker is able to detect fast-growing primary prostate cancer.
Treatment with mushroom powder led to reduction in prostate-specific antigen level in some patients with biochemical recurrence.
A combination therapy increased survival rates for individuals with newly diagnosed metastatic, hormone-sensitive prostate cancer.
Approximately 97% of men with advanced prostate cancer report being comfortable discussing their symptoms with their health care team. But the number of men who actually do so is significantly lower.
No new safety signals were identified for long-term denosumab therapy in patients with metastatic breast or prostate cancer and bone metastases.
Androgen deprivation therapy negative impacts the mood of patients with prostate cancer.
Relatively unaggressive prostate tumors are not likely to develop into metastatic disease or result in death.
Researchers have pinpointed a novel genetic biomarker responsible for the progression of many breast and prostate cancers.
Risk of cancer in the prostate gland may be caused by exposure to bisphenol A (BPA) during organ development
A prostate organoid grown from human embryonic stem cells has enabled researchers to show that exposure to bisphenol A (BPA) may increase prostate cancer risk.
By surrounding molecules of paclitaxel with self-assembling spheres composed of amino acids, researchers doubled tumor exposure to the drug and reduced its effects on healthy tissue.
Patients receiving treatment for prostate cancer are now more likely to receive medical care matched to their level of risk.
Cost of radiotherapy among Medicare patients varied most widely because of year of diagnosis, location of treatment, clinic type, and provider.
Shift workers do not develop prostate cancer more frequently than their day-shift colleagues, research indicates.
African American men are more likely to develop prostate cancer than European American men, and are also more than twice as likely to die from it.
ASCO 2015: 12-week dosing schedule of zoledronic acid is noninferior to a more-frequent schedule of every 4 weeks.
A single molecule appears to be the central regulator driving metastasis in prostate cancer.
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men.
Prostate cancer has five distinct types, with different ways to determine which type of tumor a patient has.
A sensor chip, able to pick up on differences in glycoprotein molecules, can improve accuracy and efficiency of prostate cancer diagnosis.
Patients with prostate cancer are now more likely to receive medical care matched to risk level.
A recent study indicates a high rate of clinical upgrading at prostatectomy, based on over ten thousand patients reviewed.
Higher radiation dose is associated with improved survival rates among men with medium- and high-risk prostate cancer.
Many men with low-risk disease being spared prostatectomy, radiation, and androgen deprivation monotherapy in favor of active surveillance.
Using watchful waiting or active surveillance to monitor men with very low- and low-risk prostate cancer is effective in many patients with localized tumors and could prevent aggressive and unnecessary treatments.
New diagnoses of prostate cancer have declined in the U.S. following the 2011 USPSTF draft recommendation regarding the use of prostate-specific antigen (PSA)-based screenings.
Age-adjusted prostate cancer-specific comorbidity index is strongly predictive of other-cause mortality, according to recent study data.
In a small clinical trial, scientists found that men with advanced prostate cancer and detection of androgen receptor splice variant-7 (AR-V7) respond to chemotherapy just as well as men who lack the variant.
Association between smoking and development of various forms of cancer well established; however, evidence of prostate cancer link contradictory.
Prostate cancer diagnoses in the United States dropped 28% in year following USPSTF draft recommendation.
Adopting or retaining a Western-style diet after a prostate cancer diagnosis does little to improve cancer-related mortality or overall mortality, when compared to a healthier diet.
Men with advanced prostate cancer who possess AR-V7 respond just as well to chemotherapy as those who lack AR-V7.
Emotionally distressed men diagnosed with prostate cancer may be more likely to opt for surgery.
Novel test combines two markers with prostate-specific antigen (PSA) for improved prostate cancer detection
A new test that employs urine analysis demonstrated improved prostate cancer detection over traditional models based on prostate-specific antigen (PSA) levels.
Hospitals may invest in expensive, robot-assisted surgical models for performing radical prostatectomies (RARPs), but patients may benefit more from an experienced surgeon performing traditional open surgery.
Depending on the type of cancer faced, the needs of survivors can vary.
Men who are receiving androgen deprivation therapy (ADT) have an increased chance of experiencing impaired cognitive function.
When is chemotherapy or radium 223 the optimal treatment for men with advanced prostate cancer?
Researchers are examining what factors might make patients with prostate cancer more likely to experience hot flashes during and after therapy.
Men with prostate cancer that has spread to nearby lymph nodes may find the addition of radiation therapy to treatments that block the effects of testosterone beneficial.
Trials results indicate that the pioneering drug olaparib, which targets inherited mutations, can be beneficial for men with prostate cancer.
Combination of docetaxel and hormone therapy can extend life by almost a year for prostate cancer patients, according to new research.
Rises in unemployment are associated with increases in deaths due to prostate cancer.
[Clinical Medicine Insights] In this case study, a 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk‑3 gene.
Men treated with androgen deprivation therapy (ADT) for prostate cancer more likely to demonstrate impaired cognitive performance.
The use of permanent radioactive implants (brachytherapy) with dose-escalated external beam radiotherapy in patients with prostate cancer doubled the chances of those individuals to be cancer-free 5 years later.
Addition of radiotherapy to hormonal therapy may improve survival in men with node-positive prostate cancer.
Statin use may slow prostate cancer progression in patients receiving androgen deprivation therapy, but more trials are needed to confirm benefits, researchers say.
Statins were shown to delay disease progression in men with prostate cancer when statins were also initiated with androgen deprivation therapy (ADT).
Treating gum disease reduced symptoms of prostate inflammation.
Postsurgical radiation therapy for prostate cancer at risk of recurrence is declining in the United States, despite evidence that it can be helpful.
For men with nonmetastatic castration resistant prostate cancer with a negative bone scan after diagnosis, factors associated with a second bone scan include higher PSA, shorter PSA doubling time, and faster PSA velocity; but under- and over-imaging may also be a factor.
An inexpensive, quick-result test has been shown in recently published studies to be more sensitive and more exacting than the current standard test for early stage prostate cancer.
Men with prostate cancer who received permanent radioactive implants (brachytherapy) were twice as likely to be cancer-free 5 years later.
Implementation of video-based decision aids for men lowered rates of elective surgery for benign prostatic hyperplasia (BPH) and decreased rates of active treatment for localized prostate cancer.
Two studies do not show protective effect of delayed radiation compared to earlier radiation for prostate cancer.
- Understanding Drug Naming Nomenclature
- Prostate-Specific Antigen (PSA) Test (Fact Sheet)
- CDK4/6 Inhibitors Exploit a Unique Vulnerability in Pancreatic Cancer
- Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed
- Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma
- Low-income Breast Cancer Survivors Benefit From Personalized Survivorship Care Plans
- Understanding Drug Naming Nomenclature
- Nurse Navigators Key to Seamless Transition From Pediatric to Adult Survivorship Care
- Common Painkiller Has Anticancer Effects
- Palliative Care is Cost Effective for Cancer Patients, and Increases With Comorbidities
- Chemotherapy-related Bone Loss in Children With ALL Occurs Earlier Than Previously Assumed
- Data Analysis Shows 8-week Chemoradiotherapy-to-Surgery Timeline Achieves Optimal Tumor Response
- Exercise During Neoadjuvant CRT Less Difficult Than Anticipated for Rectal Cancer
- Early Onset of Everolimus Adverse Events Requires Thorough Patient Education
- Nanoparticle System Uses Light Waves to Target Release Site of Drug
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|